Washington, D.C. – (November 14, 2022) A new surgical procedure successfully addresses a common lingering challenge — incontinence – faced by some families with young children who have undergone ...
MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics Inc., a biotech company focused on rare pediatric diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted both ...
FIGHTING TO GET BETTER TREATMENT OPTIONS FOR A RARE CHILDHOOD CONDITION. IT’S CALLED HIRSCHSPRUNG DISEASE. THE EARLIEST SIGN IN A NEWBORN IS OFTEN CONSTIPATION. THERE ARE TREATMENTS AVAILABLE. HERE’S ...
MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.
Neurenati Therapeutics Inc., a biotechnology company dedicated to developing transformative therapies for rare pediatric diseases, is pleased to announce that the European Medicines Agency (EMA) has ...
Hirschsprung's disease (HSCR) and anorectal malformations (ARM) comprise a spectrum of congenital disorders that affect the distal gastrointestinal tract. HSCR is typified by aganglionosis, the ...
During development of the digestive system, a complex network of nerves forms around it, creating a "second brain"—the enteric nervous system (ENS)—which controls the movement of food and waste ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results